Santhera Pharmaceuticals

Santhera is a Swiss specialty pharmaceutical company focused on the development and commercialisation of therapies for rare diseases with high unmet medical need. Its lead product, AGAMREE (vamorolone), is an approved treatment for Duchenne muscular dystrophy and is being rolled out globally through a combination of direct commercialisation and strategic licensing partnerships.

Equities

Equities by Sector

Sectors

Megatrends

Thematics

Latest

Edison explains: Why plan B is the new energy strategy

From obligation to opportunity

Why the solar eclipse is now an energy story

Audiovisual

Latest

Templeton Emerging Markets Investment Trust in 60 seconds

Templeton Emerging Markets Investment Trust in 60 seconds

VietNam Holding – equity proposition

About Edison

Corporates

Investors

Careers

Santhera Pharmaceuticals (SIX: SANN)

Latest Insights

Santhera Pharmaceuticals — Break-even in sight as AGAMREE scales

Santhera Pharmaceuticals (SWX: SANN) posts strong AGAMREE growth

Santhera Pharmaceuticals Holding (SIX: SANN) – FY24 results reflect AGAMREE’s strong market rollout

Market Data

Sector

Equity Analyst

Key Management

Share Price Chart

Research

Edison explains: Investing in health stocks – how policy clarity is opening doors

The CNS renaissance: Innovations are reshaping neurological therapies

Healthcare-focused trusts: A sector on the mend

Outlook for 2024: Life sciences – where has the conviction gone?

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

VolitionRx – Decoding the DNA of cancer

ASCO 2023 key takeaways

Machine learning in drug development

Outlook for 2023: Biotechs remain central to novel drug development

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

Cell and gene therapies

Drug delivery platforms

Oncology ABCs (part three) – thinking outside the box in women’s cancer

Neuroscience comeback

IPO apocalypse

Oncology ABCs (part two) – vaccines: niche no longer

ESG, moving beyond the box tick

Oncology ABCs (part one) – a small-cap biopharma prospectus series

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

Artificial intelligence in drug discovery

Biosynthesis – Taking the cannabinoid market to new heights

Seven things every investor should know about SIGA technologies & biological weapons

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

Edison Exhibits- antibiotic development

The next wave in AMD

The A-B-T of biosimilars- Explaining contemporary life science issues

Cannabinoid Therapies- The coming retail wave

Cannabinoid Therapies- Therapeutics turning a corner

Trial outcomes and value – Explaining contemporary clinical trial issues

Drug pricing – Market access and reimbursement

The diagnostics sector

ASCO 2017

Deutsche Börse Eigenkapitalforum 2014 Research Guide

Edison healthcare quarterly: A boost for allergy immunotherapy

ASX Spotlight Conference – London, 6 March 2014

ASX Small to Mid Caps Conference – London, 7 March 2013

Edison healthcare quarterly: Boom times for US biotech

Edison healthcare quarterly: Crisis? What crisis?

Edison healthcare quarterly: How to please some of the people some of the time